Clinical Trial

ACTengine® IMA203 Combined With mRNA-4203

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-04-19; most recent amendment 2026-01-06.
Status change: Not Yet Recruiting → Recruiting 2025-08-26
Trial Details
NCT Number NCT06946225
Lead Sponsor Immatics US, Inc.
Collaborators: ModernaTX, Inc.
Conditions Cutaneous Melanoma, Synovial Sarcoma
Enrollment 15 participants
Start Date 2025-07-25
Primary Completion 2029-08 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2026-01-08